降血脂藥物與移植後新診斷糖尿病風險

10.6666/ClinMed.202006_85(6).0063

陳紀瑜；歐朔銘

末期腎病（end-stage kidney disease） ； 空腹血糖異常（impaired fasting glucose） ； 腎臟移植（kidney transplantation） ； 移植後新診斷糖尿病（new-onset diabetes after transplantation） ； 史塔丁類降血脂藥物（statins）

臨床醫學月刊

85卷6期（2020 / 06 / 26）

340 - 343

繁體中文

腎臟移植後，血脂異常會引發移植器官的血管損傷，進而增加移植失敗率以及心血管疾病的發病率及死亡率，因此史塔丁類降血脂藥物（statins）常被用於高血脂症。但statins也有一個可能的副作用，就是會增加血糖異常和糖尿病的風險。不過在有限的文獻搜尋裡，statins大多造成的是空腹血糖異常，與糖尿病未必有顯著相關性。所以，衡量利弊之後，使用statins來降低心血管事件發生的好處還是遠大於發生新診斷糖尿病的壞處。但使用statins後，臨床醫師須有較高的警覺性來定期追蹤空腹血糖值及糖化血色素，以期及早發現血糖異常和新發糖尿病的發生。

1. Arner, P,Gunnarsson, R,Blomdahl, S(1983).Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy.Diabetes Care,6,23-25.
2. Asberg, A(2003).Asberg AInteractions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.Drugs,63,367-378.
3. Brault, M,Ray, J,Gomez, YH(2014).Statin treatment and new-onset diabetes: a review of proposed mechanisms.Metabolism,63,735-745.
4. Choe, Eun Yeong,Wang, Hye Jin,Obin, Kwon(2014).HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients.Transplantation,97,419-425.
5. Cosio, FG,Kudva, Y,van der Velde, M(2005).New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.Kidney Int,67,2415-2421.
6. Hermann, M,Asberg, A,Christensen, H(2004).Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.Clin Pharmacol Ther,76,388-391.
7. Holdaas, H,Fellstrom, B,Jardine, AG(2003).Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebocontrolled trial.Lancet,361,2024-2031.
8. Jindal, RM,Sidner, RA,Milgrom, ML(1997).Post-transplant diabetes mellitus. The role of immunosuppression.Drug Saf,16,242-257.
9. Kang, ES,Kim, MS,Kim, CH(2009).Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea.Transplantation,88,693-698.
10. Kang, ES,Magkos, F,Kim, BS(2012).Variants of the adiponectin and adiponectin receptor-1 genes and posttransplantation diabetes mellitus in renal allograft recipients.J Clin Endocrinol Metab,97,129-135.
11. Kasiske, BL,Snyder, JJ,Gilbertson, D(2003).Diabetes mellitus after kidneytransplantation in the United States.Am J Transplant,3,178-185.
12. Katzir, Z,Leibovitch, E,Vaknin, H(2013).Effect of atorvastatin on IgA nephropathy in the rat.Clin Nephrol,79,214-220.
13. Kim, YG,Ihm, CG,Lee, TW(2012).Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation.Transplantation,93,900-907.
14. Koh, KK(2013).Letter by Koh regarding article, “Statins and risk of new- onset diabetes mellitus＂.Circulation,127,e837.
15. Lane, JT,Dagogo-Jack, S(2011).Approach to the patient with new-onset diabetes after transplant (NODAT).J Clin Endocrinol Metab,96,3289-3297.
16. Lee, HC(2012).Post-renal transplant diabetes mellitus in korean subjects: superimposition of transplantrelated immunosuppressant factors on genetic and type 2 diabetic risk factors.Diabetes Metab J,36,199-206.
17. Leung, A,Schaefer, EW,Tempelhof, MW(2012).Emphasizing statin safety in the hospitalized patient: a review.Am J Med,125,845-853.
18. Lim, S,Sakuma, I,Quon, MJ(2013).Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.Int J Cardiol,167,1696-1702.
19. Naomi, Nacasch,Ze´ev, Korzets(2009).Worsening of hyperglycemia due to atorvastatin in a renal transplant patient.NDT Plus,2,392-394.
20. Naveed, Sattar,David, Preiss(2010).Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.Lancet,375,735-742.
21. Neuvonen, PJ,Backman, JT,Niemi, M(2008).Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.Clin Pharmacokinet,47,463-474.
22. Neuvonen, PJ,Niemi, M,Backman, JT(2006).Drug interactions with lipid- lowering drugs: mechanisms and clinical relevance.Clin Pharmacol Ther,80,565-581.
23. Ozbay, LA,Smidt, K,Mortensen, DM(2011).Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.Br J Pharmacol,162,136-146.
24. Penfornis, A,Kury-Paulin, S.(2006).Immunosuppressive drug-induced diabetes.Diabetes Metab,32,539-546.
25. Pereira, MJ,Palming, J,Rizell, M(2013).The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue.Mol Cell Endocrinol,365,260-269.
26. Pham, PT,Pham, PC,Lipshutz, GS(2007).New onset diabetes mellitus after solid organ transplantation.Endocrinol Metab Clin North Am,36,873-890.
27. Prokai, A,Fekete, A,Pasti, K(2012).The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.Pediatr Diabetes,13,81-91.
28. Staatz, CE,Goodman, LK,Tett, SE(2010).Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and phar- macodynamics of calcineurin inhibitors: Part I.Clin Pharmacokinet,49,141-175.
29. Sulanc, E,Lane, JT,Puumala, SE(2005).New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines.Transplantation,80,945-952.
30. Yates, CJ,Fourlanos, S,Hjelmesaeth, J(2012).Newonset diabetes after kidney transplantation-changes and challenges.Am J Transplant,12,820-828.